National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
Topics
- Antibiotics (1)
- Antimicrobial Stewardship (1)
- COVID-19 (1)
- Diagnostic Safety and Quality (1)
- Healthcare-Associated Infections (HAIs) (1)
- (-) Healthcare Costs (8)
- Human Immunodeficiency Virus (HIV) (2)
- (-) Infectious Diseases (8)
- Patient Safety (1)
- Pregnancy (1)
- (-) Prevention (8)
- Public Health (2)
- Screening (1)
- Surgery (1)
- Vaccination (3)
- Women (2)
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 8 of 8 Research Studies DisplayedBartsch SM, O'Shea KJ, Wedlock PT
The benefits of vaccinating with the first available COVID-19 coronavirus vaccine.
This study’s objective was to determine quantitatively the benefits of early vaccination for COVID-19 even if later on in the pandemic a latter vaccine has substantially higher efficacy. The team developed this model in 2020 before vaccinations became available. For example if a vaccine with 50% efficacy becomes available when 10% of the population has already been infected, waiting until 40% of the population are infected for a vaccine with 80% efficacy results in 15.6 million additional cases and 1.5 million additional hospitalizations, costing $20.6 billion more in direct medical costs and $12.4 billion more in productivity losses.
AHRQ-funded; HS028165.
Citation: Bartsch SM, O'Shea KJ, Wedlock PT .
The benefits of vaccinating with the first available COVID-19 coronavirus vaccine.
Am J Prev Med 2021 May;60(5):605-13. doi: 10.1016/j.amepre.2021.01.001..
Keywords: COVID-19, Vaccination, Healthcare Costs, Prevention, Infectious Diseases
Rodriguez PJ, Roberts DA, Meisner J
Cost-effectiveness of dual maternal HIV and syphilis testing strategies in high and low HIV prevalence countries: a modelling study.
Dual HIV and syphilis testing might help to prevent mother-to-child transmission (MTCT) of HIV and syphilis through increased case detection and treatment. In this study, the investigators aimed to model and assess the cost-effectiveness of dual testing during antenatal care in four countries with varying HIV and syphilis prevalence. The authors concluded that incorporating dual rapid diagnostic tests in antenatal care could be cost-saving across countries with varying HIV prevalence.
AHRQ-funded; HS013853.
Citation: Rodriguez PJ, Roberts DA, Meisner J .
Cost-effectiveness of dual maternal HIV and syphilis testing strategies in high and low HIV prevalence countries: a modelling study.
Lancet Glob Health 2021 Jan;9(1):e61-e71. doi: 10.1016/s2214-109x(20)30395-8..
Keywords: Human Immunodeficiency Virus (HIV), Infectious Diseases, Prevention, Pregnancy, Women, Diagnostic Safety and Quality, Healthcare Costs
Skaathun B, Pho MT, Pollack HA
Comparison of effectiveness and cost for different HIV screening strategies implemented at large urban medical centre in the United States.
This analysis compared the effectiveness and cost of three HIV testing strategies in a high HIV burden area in the U.S. in identifying new HIV infections. The investigators performed a cost analysis comparing three HIV testing strategies in Chicago: (1) routine screening (RS) in an inpatient and outpatient setting, (2) modified partner services (MPS) among networks of the recently HIV infected and diagnosed, and (3) a respondent drive sampling (RDS)-based social network (SN) approach targeting young African-American men who have sex with men.
AHRQ-funded; HS000084.
Citation: Skaathun B, Pho MT, Pollack HA .
Comparison of effectiveness and cost for different HIV screening strategies implemented at large urban medical centre in the United States.
J Int AIDS Soc 2020 Oct;23(10):e25554. doi: 10.1002/jia2.25554..
Keywords: Human Immunodeficiency Virus (HIV), Screening, Healthcare Costs, Prevention, Infectious Diseases
Bartsch SM, Asti L, Stokes-Cawley OJ
The potential economic value of a Zika vaccine for a woman of childbearing age.
The authors mapped the Zika vaccine and vaccination characteristic thresholds at which vaccination becomes cost effective, highly cost effective, and cost saving. They developed a Markov model to simulate a woman of childbearing age to follow the potential risk and clinical course of a Zika infection. They found that, in some cases, the vaccine was cost effective when the risk was as low as 0.015%, the cost was as high as $7,500, the efficacy was as low as 25%, and the duration of protection was 1 year. They concluded that the thresholds at which vaccination becomes cost effective and cost saving can provide targets for Zika vaccine development and implementation.
AHRQ-funded; HS023317.
Citation: Bartsch SM, Asti L, Stokes-Cawley OJ .
The potential economic value of a Zika vaccine for a woman of childbearing age.
Am J Prev Med 2020 Mar;58(3):370-77. doi: 10.1016/j.amepre.2019.10.023..
Keywords: Vaccination, Women, Infectious Diseases, Public Health, Healthcare Costs, Prevention
Malloy GSP, Brandeau ML, Goldhaber-Fiebert JD
Modeling the cost-effectiveness of interventions to prevent plague in Madagascar.
The authors assessed the cost-effectiveness of plague (Yersinia pestis) control interventions recommended by the World Health Organization with particular consideration to intervention coverage and timing. They calculated costs, quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios from a healthcare perspective. The preferred intervention, using a cost-effectiveness threshold of $1350/QALY, was expanded access to antibiotic treatment with doxycycline with 100% coverage starting immediately after the first reported case, gaining 543 QALYs at an incremental cost of $1023/QALY gained. Sensitivity analyses support expanded access to antibiotic treatment and leave open the possibility that mass distribution of doxycycline prophylaxis or mass distribution of malathion could be cost-effective.
AHRQ-funded; HS026128.
Citation: Malloy GSP, Brandeau ML, Goldhaber-Fiebert JD .
Modeling the cost-effectiveness of interventions to prevent plague in Madagascar.
Trop Med Infect Dis 2021 Jun 11;6(2). doi: 10.3390/tropicalmed6020101..
Keywords: Infectious Diseases, Healthcare Costs, Public Health, Prevention
Bartsch SM, Avelis CM, Asti L
The economic value of identifying and treating Chagas disease patients earlier and the impact on Trypanosoma cruzi transmission.
Researchers evaluated the economic value of identifying and treatment Chagas disease patients as early as possible. Chagas disease is a parasitic disease which effects many people around the world. Investigators went to a village in Yucatan, Mexico with a population of 2,000 and evaluated impact and economic outcomes of identifying and treating patients in acute and indeterminate states of the disease. They estimated the number of acute cases averted, the number of chronic cases, disability-adjusted life years (DALYs), and savings from the cost of treating more advanced stages of the disease.
AHRQ-funded; HS023317.
Citation: Bartsch SM, Avelis CM, Asti L .
The economic value of identifying and treating Chagas disease patients earlier and the impact on Trypanosoma cruzi transmission.
PLoS Negl Trop Dis 2018 Nov 5;12(11):e0006809. doi: 10.1371/journal.pntd.0006809..
Keywords: Healthcare Costs, Infectious Diseases, Prevention
Kline SE, Sanstead EC, Johnson JR
Cost-effectiveness of pre-operative Staphylococcus aureus screening and decolonization.
In this study, the investigators developed a decision analytic model to evaluate the impact of a preoperative Staphylococcus aureus decolonization bundle on surgical site infections (SSIs), health-care-associated costs (HCACs), and deaths due to SSI. The investigators predict that the treat-all strategy would be the most effective and cost-saving strategy for preventing SSIs. However, they concluded that because this strategy might select more extensively for mupirocin-resistant S. aureus and cause more medication adverse effects than the test-and-treat approach or the SOC, additional studies are needed to define its comparative benefits and harms.
AHRQ-funded; HS022912.
Citation: Kline SE, Sanstead EC, Johnson JR .
Cost-effectiveness of pre-operative Staphylococcus aureus screening and decolonization.
Infect Control Hosp Epidemiol 2018 Nov;39(11):1340-46. doi: 10.1017/ice.2018.228..
Keywords: Surgery, Antibiotics, Antimicrobial Stewardship, Healthcare-Associated Infections (HAIs), Infectious Diseases, Patient Safety, Prevention, Healthcare Costs
Fitzpatrick MC, Shah HA, Pandey A
One Health approach to cost-effective rabies control in India.
The authors developed a data-driven rabies transmission model fit to human rabies autopsy data and human rabies surveillance data from Tamil Nadu, India. They found that highly feasible strategies focused on stray dogs, vaccinating as few as 7% of dogs annually, could very cost-effectively reduce human rabies deaths by 70% within 5 years, and a modest expansion to vaccinating 13% of stray dogs could cost-effectively reduce human rabies by almost 90%. Futher, if owners are willing to bring dogs to central point campaigns at double the rate that campaign teams can capture strays, expanded annual targets become cost-effective.
AHRQ-funded; HS000055.
Citation: Fitzpatrick MC, Shah HA, Pandey A .
One Health approach to cost-effective rabies control in India.
Proc Natl Acad Sci U S A 2016 Dec 20;113(51):14574-81. doi: 10.1073/pnas.1604975113.
.
.
Keywords: Healthcare Costs, Infectious Diseases, Prevention, Vaccination